This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hardesty, C. T. Articles by Mead, J. A. R. Search for Related Content PubMed PubMed Citation Articles by Hardesty, C. T. Articles by Mead, J. A. R.

The Use of Dihydrofolate Reductase as a Signal for Scheduling Optimal Treatment with Antileukemic Agents¹

Microbiological Associates, Inc. [C. T. H., D. C.], and National Cancer Institute, NIH [J. A. R. M.], Bethesda, Maryland 20014

High levels of dihydrofolate reductase present in an antifolate-resistant leukemia L1210 in mice can be used to assess tissue levels of leukemic cells by measurement of reductase activity. The initial rise in enzyme activity has been used as a signal for initiation of drug treatment, making it possible to administer therapy at an appropriate time late in the course of the disease rather than according to a predetermined schedule.

¹ This investigation was supported in part by Contract PH43-68-1283 with Chemotherapy, National Cancer Institute, NIH, Bethesda, Md. 20014.

Received 7/28/71. Accepted 11/18/71.